NAB-Paclitaxel Plus Carboplatin As First-Line Therapy for Patients with Advanced NSCLC in the Real-World Setting: Safety Results of the Non-Interventional Neptun Study

被引：0
|
作者：
Dechow, Tobias [1 ]
Riera-Knorrenschild, Jorge [2 ]
Hackanson, Bjoern [3 ]
von Weikersthal, Ludwig Fischer [4 ]
Chiabudini, Marco [5 ]
Timm, Barbara [5 ]
Zerbes, Ralf Michael [5 ]
Potthoff, Karin [5 ]
机构：
[1] Onkol Hamatol Ravensburg, Ravensburg, Germany
[2] Univ Klinikum Giessen & Marburg GmbH, Marburg, Germany
[3] Univ Klinikum Augsburg, Augsburg, Germany
[4] Gesundheitszentrum St Marien GmbH, Amberg, Georgia
[5] IOMEDICO AG, Freiburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
276
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [1] Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study.
    Dechow, Tobias Nicolaas
    Riera-Knorrenschild, Jorge
    Hackanson, Bjorn
    von Weikersthal, Ludwig Fischer
    Schulz, Holger
    Chiabudini, Marco
    Timm, Barbara
    Zerbes, Ralf
    Potthoff, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study
    Dechow, T.
    Riera-Knorrenschild, J.
    Schulz, H.
    Janssen, J.
    Chiabudini, M.
    Koszinowski, S.
    Potthoff, K.
    Runkel, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 296 - 296
  • [3] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjoern
    Janssen, Jan
    Schulz, Holger
    Chiabudini, Marco
    Fischer von Weikersthal, Ludwig
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    CANCER MEDICINE, 2021, 10 (22): : 8127 - 8137
  • [4] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjorn
    Janssen, Jan
    Schulz, Holger
    Oppermann, Ursula
    Chiabudini, Marco
    von Weikersthal, Ludwig Fischer
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 141 - 152
  • [5] First-Line Nivolumab plus Nab-Paclitaxel plus Carboplatin (C) in Advanced NSCLC
    Waterhouse, David
    Derosa, William
    Fraser, Cindy Duval
    Gutierrez, Martin
    Ko, Amy
    Ong, Teng Jin
    Pierce, Daniel
    Stergiopoulos, Sotirous
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S427 - S428
  • [6] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsh, Vera
    Owen, Scott
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S584 - S584
  • [7] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Gemcitabine plus nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study
    Yamaguchi, T.
    Ueno, H.
    Sasaki, M.
    Sakamoto, Y.
    Kondo, S.
    Morizane, C.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2016, 27 : 35 - 35
  • [9] Comparison of efficacy and safety of carboplatin combined with nab-paclitaxel or paclitaxel as first-line therapy for advanced thymic epithelial tumors
    Hao, Y.
    Si, J.
    Wei, J.
    Gu, X.
    Wang, W.
    Zhang, Y.
    Guan, Y.
    Huang, H.
    Xu, C.
    Song, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S157 - S158
  • [10] Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
    Arciero, Vanessa
    Luo, Jin
    Parmar, Ambica
    Dai, Wei Fang
    Beca, Jaclyn M.
    Raphael, Michael J.
    Isaranuwatchai, Wanrudee
    Habbous, Steven
    Tadrous, Mina
    Earle, Craig C.
    Biagi, Jim J.
    Mittmann, Nicole
    Arias, Jessica
    Gavura, Scott
    Chan, Kelvin K. W.
    JNCI CANCER SPECTRUM, 2022, 6 (04)
12345